Cadrenal Therapeutics

Update in progress

CVKD (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on therapies for rare cardiovascular disorders. It is developing Tecarfarin, an oral, reversible anticoagulant for patients requiring chronic anticoagulation to prevent heart attack, stroke, and death from clots. Target groups include LVAD patients, end-stage kidney disease, atrial fibrillation, and thrombotic antiphospholipid syndrome. The company collaborates with Abbott to evaluate Tecarfarin in LVAD patients. Founded in 2022, it is based in Ponte Vedra, Florida.

Company score

Sentiment: 0.01; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.00; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive